Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35,439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: song y. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
[MEKK2 regulates the production of interleukin 2].
Wei XD, Fan RH, Zhu XH, Li YF, Zhang YL, Gao QL, Liu YY, Wang P, Song YP. Wei XD, et al. Zhonghua Xue Ye Xue Za Zhi. 2005 May;26(5):296-8. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 15949294 Chinese.
Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
Fang B, Song Y, Han Z, Wei X, Lin Q, Zhu X, Yang R, Sun J, Tian G, Liu X, Cao G, Shi Y, Nie N, Li D, Zhao RC. Fang B, et al. Among authors: song y. Leuk Res. 2007 Oct;31(10):1441-4. doi: 10.1016/j.leukres.2007.02.004. Epub 2007 Mar 23. Leuk Res. 2007. PMID: 17383001 Clinical Trial.
Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
Fang B, Li N, Song Y, Han Q, Zhao RC. Fang B, et al. Among authors: song y. Ann Hematol. 2010 Nov;89(11):1099-105. doi: 10.1007/s00277-010-0991-4. Epub 2010 May 25. Ann Hematol. 2010. PMID: 20499235 Clinical Trial.
Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY, Huang XJ, Cai Z, Cao XS, Chen FP, Chen XQ, Chen BA, Fang MY, Feng JF, Fu WL, Guo HY, Hou M, Hou J, Hu Y, Hu XT, Hu XM, Huang LQ, Jin J, Li JY, Li J, Li W, Liang YM, Liu T, Liu QF, Liu YH, Mao P, Ouyang J, Qiu LG, Qiu L, Shao CK, Shi B, Song YP, Sun ZM, Wang QS, Wang C, Wang JM, Wang YS, Wang Z, Wu JB, Wu YX, Xia RX, Xue YQ, Yang BZ, Yang G, Yang ZL, Yu L, Yuan Z, Zhang S, Zhang Y, Zhao HG, Zhao L, Zhou DB, Zou SH, Zhu YF. Lai YY, et al. Among authors: song yp. Chin Med J (Engl). 2012 Aug;125(15):2663-70. Chin Med J (Engl). 2012. PMID: 22931972
35,439 results
You have reached the last available page of results. Please see the User Guide for more information.